Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

'Pan-RAS molecular glue' drug ERAS-0015 shows safety and efficacy in Phase I trials for lung and pancreatic cancers

Just now November 21, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

A new anticancer drug called ERAS-0015 has shown promising results in Phase I clinical trials for treating lung and pancreatic cancers. The drug uses 'pan-RAS molecular glue' technology and demonstrated safety and tumor shrinkage in patients with difficult-to-treat cancers. This development has no direct relevance to Iran's political, economic, military, or human rights situation.

Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →